simendan has been researched along with n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (80.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Endoh, M; Takahashi, R; Talukder, MA | 2 |
| Endoh, M; Takahashi, R | 1 |
| Edes, I; Haikala, H; Kaheinen, P; Levijoki, J; Papp, Z; Pollesello, P; Szilágyi, S | 1 |
| Antila, S; Eha, J; Heikkilä, A; Kivikko, M; Lehtonen, L; Pentikäinen, PJ; Pohjanjousi, P | 1 |
| Antila, S; Lehtonen, L; Nikkanen, H; Pesonen, U; Scheinin, H; Tapanainen, P; Vaahtera, K | 1 |
| Bagi, Z; Edes, I; Erdei, N; Papp, Z; Pollesello, P | 1 |
| Häkkinen, S; Koskinen, M; Laine, T; Pentikäinen, P; Pradhan, R; Puttonen, J; Ramela, M; Zhang, W | 1 |
| Banfor, PN; Campbell, TJ; Cox, BF; Fryer, RM; Marsh, KC; Polakowski, JS; Preusser, LC; Reinhart, GA | 1 |
| Koskinen, M; Lotta, T; Puttonen, J; Pykäläinen, M; Vuorela, A | 1 |
| Harjola, VP; Jurkko, R; Nieminen, MS; Oikarinen, L; Puttonen, J; Sarapohja, T; Sundberg, S; Toivonen, L | 1 |
| Chen, XY; Jiang, CM; Li, GX; Li, SR; Zhang, YF; Zhong, DF | 1 |
| Colucci, WS; Karlsson, MO; Kivikko, M; Pohjanjousi, P; Sundberg, S | 1 |
| Bagi, Z; Edes, I; Gödény, I; Papp, Z; Pollesello, P | 1 |
| Berthomieu, L; Bourgoin, P; Chenouard, A; Davril, E; Duflot, T; Joram, N; Lamoureux, F; Lecomte, J; Oualha, M; Pereira, T | 1 |
5 trial(s) available for simendan and n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide
| Article | Year |
|---|---|
Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan.
Topics: Acetamides; Cardiotonic Agents; Female; Heart Failure; Humans; Hydrazones; Infusions, Intravenous; Male; Protein Binding; Pyridazines; Simendan | 2004 |
Pharmacokinetics of levosimendan and its active metabolite OR-1896 in rapid and slow acetylators.
Topics: Acetamides; Acetylation; Adult; Area Under Curve; Arylamine N-Acetyltransferase; Blood Proteins; Carbon Radioisotopes; Cardiotonic Agents; Genotype; Half-Life; Humans; Hydrazones; Infusions, Intravenous; Male; Protein Binding; Pyridazines; Simendan; Time Factors | 2004 |
Pharmacokinetics and excretion balance of OR-1896, a pharmacologically active metabolite of levosimendan, in healthy men.
Topics: Acetamides; Adult; Breath Tests; Carbon Radioisotopes; Feces; Humans; Hydrazones; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Molecular Conformation; Pyridazines; Reference Values; Simendan; Time Factors | 2007 |
The hemodynamic and pharmacokinetic interactions between chronic use of oral levosimendan and digoxin in patients with NYHA Classes II-III heart failure.
Topics: Acetamides; Administration, Oral; Aged; Area Under Curve; Cardiotonic Agents; Chronic Disease; Digoxin; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Heart Failure; Hemodynamics; Humans; Hydrazones; Magnetocardiography; Male; Middle Aged; Pyridazines; Simendan | 2008 |
Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients.
Topics: Acetamides; Acetylation; Double-Blind Method; Female; Follow-Up Studies; Heart Failure; Hemodynamics; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Severity of Illness Index; Simendan; Treatment Outcome; Vasodilator Agents | 2011 |
10 other study(ies) available for simendan and n-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide
| Article | Year |
|---|---|
Effects of OR-1896, an active metabolite of levosimendan, on contractile force and aequorin light transients in intact rabbit ventricular myocardium.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Acetamides; Aequorin; Animals; Cardiotonic Agents; Cyclic Nucleotide Phosphodiesterases, Type 3; Hydrazones; Isoproterenol; Male; Myocardial Contraction; Papillary Muscles; Pyridazines; Rabbits; Simendan; Stimulation, Chemical; Ventricular Function, Right | 2000 |
Inotropic effects of OR-1896, an active metabolite of levosimendan, on canine ventricular myocardium.
Topics: Acetamides; Animals; Bupranolol; Calcium; Cardiotonic Agents; Cyclic AMP; Dogs; Dose-Response Relationship, Drug; Female; Hydrazones; In Vitro Techniques; Isoproterenol; Male; Myocardial Contraction; Pyridazines; Simendan | 2000 |
Effects of OR-1896, a metabolite of levosimendan, on force of contraction and Ca2+ transients under acidotic condition in aequorin-loaded canine ventricular myocardium.
Topics: Acetamides; Acidosis; Aequorin; Animals; Calcium; Dogs; Dose-Response Relationship, Drug; Female; Heart Ventricles; Hydrazones; Male; Myocardial Contraction; Pyridazines; Simendan | 2002 |
The effects of levosimendan and OR-1896 on isolated hearts, myocyte-sized preparations and phosphodiesterase enzymes of the guinea pig.
Topics: Acetamides; Animals; Cell Separation; Dose-Response Relationship, Drug; Female; Guinea Pigs; Heart Ventricles; Hydrazones; In Vitro Techniques; Isoenzymes; Male; Myocytes, Cardiac; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Pyridazines; Simendan; Ventricular Function | 2004 |
The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles.
Topics: Acetamides; Animals; Arterioles; Coronary Vessels; Hydrazones; Large-Conductance Calcium-Activated Potassium Channels; Male; Muscle, Skeletal; Potassium Channels; Pyridazines; Rats; Rats, Wistar; Simendan; Vasodilation; Vasodilator Agents | 2006 |
Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
Topics: Acetamides; Animals; Blood Pressure; Calcium; Cardiac Output; Cardiotonic Agents; Cardiovascular System; Dobutamine; Dogs; Dose-Response Relationship, Drug; Heart Rate; Hydrazones; Male; Milrinone; Myocardial Contraction; Oxygen Consumption; Potassium; Potassium Channels; Pulmonary Circulation; Pyridazines; Simendan; Time Factors; Vascular Resistance; Vasodilator Agents; Ventricular Function, Left | 2008 |
Metabolism of OR-1896, a metabolite of levosimendan, in rats and humans.
Topics: Acetamides; Adult; Animals; Cardiotonic Agents; Humans; Hydrazones; Male; Middle Aged; Pyridazines; Rats; Rats, Sprague-Dawley; Simendan | 2008 |
[Determination of levosimendan and its main metabolites in human plasma with HPLC-MS/MS method].
Topics: Acetamides; Cardiotonic Agents; Chromatography, High Pressure Liquid; Humans; Hydrazones; Male; Pyridazines; Simendan; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2008 |
Levosimendan and its metabolite OR-1896 elicit KATP channel-dependent dilation in resistance arteries in vivo.
Topics: Acetamides; Animals; Arterioles; Dose-Response Relationship, Drug; Hydrazones; KATP Channels; Male; Microscopy, Video; Muscle, Smooth; Potassium Channel Blockers; Pyridazines; Rats; Rats, Wistar; Simendan; Vascular Resistance; Vasodilation; Vasodilator Agents | 2013 |
Population Pharmacokinetics of Levosimendan and its Metabolites in Critically Ill Neonates and Children Supported or Not by Extracorporeal Membrane Oxygenation.
Topics: Anti-Bacterial Agents; Child; Critical Illness; Extracorporeal Membrane Oxygenation; Humans; Infant, Newborn; Prospective Studies; Simendan | 2023 |